EE512 Potential Long-Term Benefits of Extended Adjuvant Neratinib in Patients with High-Risk Hormone Receptor Positive (HR+) HER2+ Early-Stage Breast Cancer (ESBC) Following Use of T-DM1 or Pertuzumab: A Population Effectiveness Model
Veenstra, D., Oestreicher, N., Dolan, C.M., Fisher, K.A., Pandey, R., Elsea, D., Brufsky, A.
Published in Value in health (01.06.2023)
Published in Value in health (01.06.2023)
Get full text
Journal Article
161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Veenstra, D.L., Hendrix, N., Dolan, C.M., Fisher, K.A., Lalla, D., Oestreicher, N., Moy, B.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Serum IgE and lung function in the TENOR asthma cohort
Borish, L.C., Miller, M.K., Zheng, B., Dolan, C.M., Deniz, Y.
Published in Journal of allergy and clinical immunology (01.02.2004)
Published in Journal of allergy and clinical immunology (01.02.2004)
Get full text
Journal Article
High medication usage in a large cohort of patients with severe or difficult-to-treat asthma
Johnson, C., Chipps, B.E., Dolan, C.M., Warren, E.H.
Published in Journal of allergy and clinical immunology (01.02.2003)
Published in Journal of allergy and clinical immunology (01.02.2003)
Get full text
Journal Article